Stay updated on Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.

Latest updates to the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check10 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed information about a clinical trial for Daratumumab, a drug for treating Monoclonal Gammopathy and Smoldering Multiple Myeloma, and the addition of new collaborators and a revision number.SummaryDifference45%
- Check53 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 5, 2025.SummaryDifference0.2%
- Check61 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in High-Risk MGUS & Low-Risk Smoldering Clinical Trial page.